MBTC Business Summary

Microbase Technology Corp. (MBTC) operates a high-precision manufacturing business model centered on non-silicon-based micro-electro-mechanical systems (MEMS) using proprietary LIGA (Lithography, Electroforming, and Molding) technology. The company generates revenue through the design, manufacture, and sale of advanced micro-atomization components and finished medical devices, alongside industrial inkjet head nozzle plates. Its primary business segments include Medical Devices, which features the Pocket Air® and GOCare™ vibrating mesh nebulizers and the SOMIST™ soft mist inhaler, and Electronic Components, which supplies high-density nozzle plates for the global printing and packaging industries. MBTC also provides Contract Development and Manufacturing Organization (CDMO) services for transdermal microneedle patches and microfluidic systems. Within the competitive landscape, MBTC competes directly with global respiratory leaders such as Aerogen, Omron Corporation, and PARI GmbH, as well as regional precision component manufacturers like Taiwan Precision Components (TPC). MBTC distinguishes itself through its specialized use of polyimide materials and a robust portfolio of over 450 patents, positioning it as a high-tier technology provider in the precision drug delivery market. Founded in 1997 with support from Taiwan’s Industrial Technology Research Institute (ITRI), MBTC is led by a management team with deep expertise in micrometer-level engineering and biotechnology. The current leadership is headed by Chairman Xin Li, who oversees the company’s strategic expansion into international healthcare markets, supported by a board that includes directors Yao Yu Du and Yang Fu Guo. Key technical and operational roles are filled by veterans of the Taiwanese semiconductor and medical device sectors, including Spokesperson Rick Liu, who manages the firm’s regulatory and public disclosures. The company’s stability is reinforced by a concentrated ownership structure, with major stakeholders including Jinhushen Biomedical Technology Co., Ltd., Zhouxin Co., Ltd., and significant individual investors such as Yu-Ren Chen and Xian Meng. This leadership group has successfully navigated the company through rigorous international certifications, including EU MDR and US FDA clearances, to transition MBTC from a component supplier to a global brand in respiratory care.